Clinical Trials Directory

Trials / Completed

CompletedNCT04616625

Cardiovascular Effects of Prenatal Methamphetamine Exposure

Status
Completed
Phase
Study type
Observational
Enrollment
26 (actual)
Sponsor
University of California, Davis · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

Methamphetamine (MA) is one of the commonly used drugs during pregnancy. Cardiovascular effects of MA include elevated blood pressure, acute vasospasm, atherosclerotic disease, structural and electrical remodeling of cardiac tissue leading to arrhythmias and heart failure, and pulmonary hypertension.1 In addition, MA can cause neurotoxicity with harmful effects on neurodevelopment in the children who had prenatal exposure.5-8 Currently neonatal providers do not perform detailed cardiovascular evaluation in newborn period or long term neurodevelopmental assessments as outpatient for the newly born infants with prenatal exposure to MA, and they do not qualify for early intervention. The goal of the investigators is to perform detailed cardiovascular evaluation in neonatal period and estimate baseline prevalences and follow up with developmental and cardiovascular assessment using a questionnaire at 12 months in a cohort of neonates enriched with those who had prenatal exposure to MA.

Conditions

Timeline

Start date
2020-10-05
Primary completion
2023-06-30
Completion
2023-06-30
First posted
2020-11-05
Last updated
2024-11-01

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT04616625. Inclusion in this directory is not an endorsement.

Cardiovascular Effects of Prenatal Methamphetamine Exposure (NCT04616625) · Clinical Trials Directory